Overview
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 2 of 3 financial statements were filed late (the longest delay 78 days for 2024).
- 2025not filed
- 202401/10/2025
- 202319/07/2024
- 202231/03/2023
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.
Results vs industry
Industry
Public procurement
Fidia Pharma Polska is the contractor in 5 public sector contracts, worth USD 7.24k in total. They were signed with 3 public buyers.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Sep 18, 2026 | Medical device – Fidial viscoelastic – 100 packs | $1,081 | Samodzielny Publiczny Kliniczny Szpital Okulistyczny w Warszawie | |
| Sep 15, 2026 | Purchase of a medical device | $702.32 | Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orłowskiego Centrum Medycznego Kształcenia Podyplomowego | |
| Aug 7, 2026 | Medicinal product | $702.32 | Samodzielny Publiczny Szpital Kliniczny Im. Prof. W. Orłowskiego Centrum Medycznego Kształcenia Podyplomowego |
Trademarks
Fidia Pharma Polska holds 2 active trademarks registered with the Polish Patent Office. The first mark was filed in 2023.
| Mark | Number | Classes | Status | Protected until | |
|---|---|---|---|---|---|
| AKSOBREX FIDIA(word) | Z.551540 | 3, 5, 10, 32 | Protected | Jan 19, 2033 | |
| AKSOBREX(word) | Z.551541 | 3, 5, 10, 32 | Protected | Jan 19, 2033 |
| Mark | Protected until | |
|---|---|---|
| AKSOBREX FIDIA(word) | Jan 19, 2033 | |
| AKSOBREX(word) | Jan 19, 2033 |
Authorized Representatives
Manner of representation
The following are authorised to represent the company and incur obligations: in the case of a one-person management board, a member of the management board acting independently; in the case of a multi-member management board, the President of the Management Board acting independently, two members of the management board acting jointly, or one member of the management board acting jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Fidia Farmaceutici S.p.a. | 20,100 | $271,474.88 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2022-04-11.
37 1600 1462 1716 2567 4000 0003- 91 1600 1462 1716 2567 4000 0001
- 10 1600 1462 1716 2567 4000 0004
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $111,469,394.21 | anpharm.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| VercoS.A. | $43,577,172.02 | verco.com.pl | ||
| MedicofarmaS.A. | $8,530,473.72 | medicofarma.pl | ||
| VitamaS.A. | $4,287,087.38 | vitama.pl | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Stg25Branch (foreign co.) | – | glagolica.eu |
Change history
| Date | Event | |
|---|---|---|
| 2023-05-22 | Address change (Ul. Towarowa 28, 00-839, Warszawa → Ul. Puławska 428, 02-884, Warszawa) | |
| 2023-01-04 | Share capital increase (5,000.00 PLN → 1,005,000.00 PLN) | |
| 2022-11-24 | Name change (Gavirfort Investments → Fidia Pharma Polska) | |
| 2022-11-24 | PKD change (Removed: 10 codes; Added: 10 codes) | |
| 2022-04-05 | Entered in the register |
FAQ
Last updated: 2026-10-07